<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137680">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660581</url>
  </required_header>
  <id_info>
    <org_study_id>Regent Vsel</org_study_id>
    <secondary_id>2011-005435-98</secondary_id>
    <nct_id>NCT01660581</nct_id>
  </id_info>
  <brief_title>Intracardiac CD133+ Cells in Patients With No-option Resistant Angina</brief_title>
  <acronym>Regent Vsel</acronym>
  <official_title>A Randomized, Prospective, Double-blind Study to Evaluate Intracardiac Injections of Bone Marrow, Autologous CD133+ Cells (Electromechanical Mapping Based) in Patients With Resistant Angina and no Effective Revascularization Option. Regent Vsel Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <authority>Poland: Komisja Bioetyczna Slaski Uniwersytet Medyczny</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of therapy with autological CD133+
      cells in patients with angina resistant to pharmacological treatment and without the
      possibility of effective revascularization. Cells will be isolated from patients bone marrow
      and administered directly into the muscle of left ventricle. The main objective is to assess
      the treatments' influence on improvement of myocardial perfusion and function, and on
      decrease of occurrence of symptomatic angina.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a Stable angina pectoris (CCS II-IV) can potentially benefit from treatment
      with autological CD133+ cell populations, which include cells with a higher expression of
      cardiac and endothelial differentiation markers.

      REGENT VSEL Trial will include Patients with Angina resistant to pharmacological treatment
      and without the possibility of effective revascularization.

      The main objective of the study is to assess the treatments influence on:

        -  improvement of myocardial perfusion

        -  global and segmental contractility (LVEF)

        -  occurrence of symptomatic angina

        -  quality of life

      Regent Vsel is a prospective, randomized, double blind, placebo-controlled study with a
      planned number of 60 Patients.

      Randomization will be carried out according to a 1:1 mode. Every Patient will undergo a bone
      marrow aspiration. CD133+ cells will be isolated from bone marrow aspirates. Patients
      randomized to experimental group will receive isolated cells (direct left ventricular muscle
      administration). Patients enrolled to control group will get only a placebo solution
      injected into the muscle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Myocardial perfusion change</measure>
    <time_frame>4 months after application of cell therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Myocardial perfusion change assessed by perfusion scintigraphy (99mTc SPECT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global and segmental contractility change and myocardial perfusion change</measure>
    <time_frame>MRI 4 months and echocardiography 4 and 12 months after application of cell therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global and segmental contractility change and myocardial perfusion change assessed by magnetic resonance imaging with adenosine administration, and echocardiography with contrast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance</measure>
    <time_frame>4 and 12 months after application of cell therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Exercise tolerance assessed in a treadmill test (TET, ESTD, TTLA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of symptomatic angina</measure>
    <time_frame>1, 4, 6 and 12 months after application of cell therapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>CCS, nitrates usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1, 4, 6 and 12 months after application of cell therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life assessed by standard questionnaires: SF37, Seattle Angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ventricular arrhythmia</measure>
    <time_frame>1, 4, 6 and 12 months after application of cell therapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>24 hrs ECG monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of in-stent restenosis and progression of artherosclerotic lesions in remained coronary artery segments</measure>
    <time_frame>4 months after application of cell therapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed by Intravascular Ultrasound (IVUS) and Optical coherence tomography (OCT) examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>CD133+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intramyocardial injection (electromechanical mapping based)</intervention_name>
    <description>Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.</description>
    <arm_group_label>CD133+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stable angina CCS II-IV despite maximum pharmacotherapy for at least 2   weeks since
             last medications change

          2. Presence of ≥ 1 myocardial segment with ischemia features in Tc-99m SPECT

          3. Patients disqualified from revascularization procedures by Heart Team

          4. Patient age &gt; 18 and &lt; 75 year old

          5. Patient must provide written informed consent for participation in study

        Exclusion Criteria:

          1. Acute coronary syndrome in less than 6 months prior to enrollment

          2. Heart failure NYHA III-IV

          3. LVEF &lt;35%

          4. Presence of intracardiac thrombus (echocardiography confirmed), massive calcification
             of the aortic valve and left ventricular aneurysm

          5. Previous cardioverter-defibrillator or cardiac stimulator implantation

          6. Allergy to contrast agents

          7. History of malignancy

          8. HIV, HBV, HCV infection

          9. Life expectancy less than 6 months

         10. Bleeding diathesis

         11. Renal insufficiency (GFR &lt; 30 mL/min/1.73m2)

         12. Pregnancy, lactation, or ineffective contraception in women of childbearing potential
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wojciech Wojakowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach Górnośląskie Centrum Medyczne III Klinika Kardiologii</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Wojakowski, MD, PhD</last_name>
    <phone>+48 32 2523930</phone>
    <email>wojtek.wojakowski@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach Górnośląskie Centrum Medyczne im. prof. Leszka Gieca</name>
      <address>
        <city>Katowice-Ochojec</city>
        <state>Silesian</state>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Wojakowski, MD, PhD</last_name>
      <phone>+48 32 2523930</phone>
      <email>wojtek.wojakowski@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wojciech Wojakowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007 May 28;167(10):989-97. Review.</citation>
    <PMID>17533201</PMID>
  </reference>
  <reference>
    <citation>Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauer BE, Vetrovec GW. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007 Oct 30;50(18):1761-7. Epub 2007 Oct 15. Review.</citation>
    <PMID>17964040</PMID>
  </reference>
  <reference>
    <citation>Wojakowski W, Tendera M, Zebzda A, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Krol M, Ochala A, Kozakiewicz K, Ratajczak MZ. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J. 2006 Feb;27(3):283-9. Epub 2005 Nov 2.</citation>
    <PMID>16267071</PMID>
  </reference>
  <reference>
    <citation>Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochala A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004 Nov 16;110(20):3213-20. Epub 2004 Nov 8.</citation>
    <PMID>15533859</PMID>
  </reference>
  <reference>
    <citation>van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP, de Roos A, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009 May 20;301(19):1997-2004.</citation>
    <PMID>19454638</PMID>
  </reference>
  <reference>
    <citation>Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):208-16. Epub 2007 Oct 19. Review.</citation>
    <PMID>17951319</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Wojciech Wojakowski MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>CD133+</keyword>
  <keyword>stem cells</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Stable Angina Pectoris</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
